December 20, 2024

Victoria Stodden to receive Humboldt Research Award

Victoria Stodden to receive Humboldt Research Award

Victoria Stodden, statistician and associate professor at the Daniel J. Epstein Department of Industrial and Systems Engineering at the University of Southern California, has been selected to receive a prestigious Humboldt Research Award.

Granted by the Alexander von Humboldt Foundation, the award is bestowed on internationally leading researchers in recognition of outstanding academic achievements. A key goal of the award is to facilitate international scientific collaboration, as awardees spend up to a year at research institutions in Germany, where they collaborate with specialist colleagues. 

“This is a very exciting step for me. The award recognizes more than a single result or paper, it is an appreciation of my entire research agenda,” said Stodden.

Stodden, who has been serving as vice-chair of the HITS Scientific Advisory Board since 2022, is a global leader in the field of reproducibility in computational and data science, exploring how the reliability and replicability of increasingly sophisticated computational approaches can be ensured. Her work also addresses standards of openness for data and code sharing, legal and policy barriers to disseminating reproducible research, and scientific publishing practices.

“Victoria Stodden’s research and expertise are of utmost importance to HITS, where computational and data science take center stage,” says Tilmann Gneiting, Scientific Director at HITS and leader of the Computational Statistics group at HITS and Karlsruhe Institute of Technology (KIT). Stodden’s research agenda also plays crucial roles at the KIT Graduate School Computational and Data Science (KCDS) where Stodden will serve as a visiting professor, supported by a KIT International Excellence Fellowship. “We very much look forward to welcoming Victoria Stodden in Heidelberg and Karlsruhe from January 2025 onwards,” say Gneiting and co-host Melanie Schienle at KIT.

Stodden earned her Ph.D. in statistics from Stanford University, and her law degree from Stanford Law School. She has served on various committees of the US National Academies of Science, Engineering, and Medicine and co-chaired the US National Science Foundation’s Advisory Committee for CyberInfrastructure. Her membership in the HITS Scientific Advisory Board will be suspended during the research stay in Germany.

Press Contact:
Dr. Peter Saueressig
Head of Communications
Heidelberg Institute for Theoretical Studies

Scientific Contact:
Prof. Dr. Tilmann Gneiting
Computational Statistics Group
Heidelberg Institute for Theoretical Studies

Our latest News

discover more
Tailor-Made Fertilization

Tailor-Made Fertilization

Excessive fertilization in agriculture weakens crops, threatens drinking water quality, and harms the soil. Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB are now developing an alternative fertilizer that is fully biodegradable, supplies plants exclusively with the nutrients they need, and prevents over-fertilization. More information in German below: Jahr für Jahr werden […]

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Professor Dr. Jessica Hassel, Faculty of Medicine Heidelberg at Heidelberg University and Head of the Skin Cancer Center at Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) Heidelberg, has been awarded in the category “Clinical Research.” Professor Dr. Dr. Felix Sahm, also from the Faculty of Medicine Heidelberg, Department of Neuropathology at […]

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp